Henriette M. E. Quarles van Ufford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Henriette M. E. Quarles van Ufford has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
John M. H. de Klerk
Department of Nuclear Medicine, Meander Medical Center, Amersfoort, The Netherlands
2 shared publicationsRob Fijnheer
Department of Hematology, Meander Medical Center, Amersfoort, The Netherlands
2 shared publicationsBianca Tieks
Nuclear Medicine, Meander Medical Center, Amersfoort, The Netherlands
1 shared publicationFrederik J. Beek
Department of Radiology, University Medical Center Utrecht, HP E.01.132, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands
1 shared publicationHarm van Tinteren
Comprehensive Cancer Center and Netherlands Cancer Institute, Amsterdam, The Netherlands
1 shared publicationHenk J. Baarslag
1 shared publication
Latest Publications
- 1 March 2011
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 196 (3) , 662-669
Newly Diagnosed Lymphoma: Initial Results With Whole-Body T1-Weighted, STIR, and Diffusion-Weighted MRI Compared With 18F-FDG PET/CT
OBJECTIVE. The purpose of this study was to compare whole-body MRI including diffusion-weighted imaging (DWI) with 18F-FDG PET/CT in the staging of newly diagnosed lymphoma.SUBJECTS AND METHODS. Twenty-two consecutively registered patients with newly diagnosed lymphoma prospectively underwent whole-body MRI (22 with T1-weighted, STIR, and DWI sequences and 21 with T1-weighted and STIR sequences but not DWI) and FDG PET/CT. Whole-body MRI-DWI was independently evaluated by two blinded observers. Interobserver agreement was assessed, and whole-body MRI-DWI was compared with FDG PET/CT.RESULTS. The kappa values for interobserver agreement on whole-body MRI-DWI for all nodal regions together and for all extranodal regions together were 0.676 and 0.452. The kappa values for agreement between whole-body MRI-DWI and FDG PET/CT for all nodal regions together and for all extranodal regions together were 0.597 and 0.507. Ann Arbor stage according to whole-body MRI-DWI findings was concordant with that of FDG PET/CT...
- 1 March 2011
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 196 (3) , 662-669
Newly Diagnosed Lymphoma: Initial Results With Whole-Body T1-Weighted, STIR, and Diffusion-Weighted MRI Compared With 18F-FDG PET/CT
OBJECTIVE. The purpose of this study was to compare whole-body MRI including diffusion-weighted imaging (DWI) with 18F-FDG PET/CT in the staging of newly diagnosed lymphoma.SUBJECTS AND METHODS. Twenty-two consecutively registered patients with newly diagnosed lymphoma prospectively underwent whole-body MRI (22 with T1-weighted, STIR, and DWI sequences and 21 with T1-weighted and STIR sequences but not DWI) and FDG PET/CT. Whole-body MRI-DWI was independently evaluated by two blinded observers. Interobserver agreement was assessed, and whole-body MRI-DWI was compared with FDG PET/CT.RESULTS. The kappa values for interobserver agreement on whole-body MRI-DWI for all nodal regions together and for all extranodal regions together were 0.676 and 0.452. The kappa values for agreement between whole-body MRI-DWI and FDG PET/CT for all nodal regions together and for all extranodal regions together were 0.597 and 0.507. Ann Arbor stage according to whole-body MRI-DWI findings was concordant with that of FDG PET/CT...
- Open Access
- 16 September 2010
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 51 (10) , 1507-1516
Added Value of Baseline 18F-FDG Uptake in Serial 18F-FDG PET for Evaluation of Response of Solid Extracerebral Tumors to Systemic Cytotoxic Neoadjuvant Treatment: A Meta-Analysis
The purpose of this study was to test the hypothesis that the level of baseline 18F-FDG uptake in the primary tumor adds value to its relative change in 18F-FDG uptake in serial PET scans in predicting the histopathologic response to systemic cytotoxic neoadjuvant treatment of patients with solid extracerebral tumors. Methods: We performed a literature search from January 1995 through November 2008 using PubMed and Embase. Two reviewers independently selected eligible studies for possible inclusion in the meta-analysis by reviewing titles and abstracts. Inclusion criteria were at least 10 patients, 18F-FDG PET before and after therapy, 18F-FDG PET performed with the intention of monitoring the response of solid extracerebral tumors in humans to cytotoxic neoadjuvant systemic therapy, attenuation-corrected 18F-FDG PET studies, and studies presenting individual patient data (PET results and histopathologic reference test after treatment). Multilevel logistic regression was used to assess the effect of relative change of 18F-FDG uptake ([baseline – end]/baseline) and baseline 18F-FDG uptake value with type of tumor and type of treatment as level 1 covariates. Results: Nineteen studies (all observational; a total of 438 patients [median, 23 patients per study; range, 10–40]) were included, aiming at the accuracy of PET versus histopathology. To quantify PET, maximum standardized uptake value (SUV) was used in 6 studies, mean SUV in 7, SUV (subtype unclear) in 1, tumor-to-background ratio in 3, and dose uptake ratio in 1. The average overall histopathologic response rate was 0.47 (median, 0.50), ranging from 0.17 to 0.88. The relative change in 18F-FDG uptake was the strongest indicator (P < 0.0001) for tumor response. Baseline 18F-FDG was not significantly associated as a main factor; however, a significant interaction of baseline uptake and relative change after therapy was observed (P < 0.001). Conclusion: Relative change in 18F-FDG uptake was the strongest indicator for tumor response, but the level of baseline 18F-FDG uptake in the primary tumor provided additional information about prediction of response to therapy. These data corroborate and extend the need for standardization, quality assurance, and control of PET studies quantifying 18F-FDG in oncologic treatment monitoring.
- 16 September 2010
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 51 (10) , 1507-1516
Open AccessAdded Value of Baseline 18F-FDG Uptake in Serial 18F-FDG PET for Evaluation of Response of Solid Extracerebral Tumors to Systemic Cytotoxic Neoadjuvant Treatment: A Meta-Analysis
The purpose of this study was to test the hypothesis that the level of baseline 18F-FDG uptake in the primary tumor adds value to its relative change in 18F-FDG uptake in serial PET scans in predicting the histopathologic response to systemic cytotoxic neoadjuvant treatment of patients with solid extracerebral tumors. Methods: We performed a literature search from January 1995 through November 2008 using PubMed and Embase. Two reviewers independently selected eligible studies for possible inclusion in the meta-analysis by reviewing titles and abstracts. Inclusion criteria were at least 10 patients, 18F-FDG PET before and after therapy, 18F-FDG PET performed with the intention of monitoring the response of solid extracerebral tumors in humans to cytotoxic neoadjuvant systemic therapy, attenuation-corrected 18F-FDG PET studies, and studies presenting individual patient data (PET results and histopathologic reference test after treatment). Multilevel logistic regression was used to assess the effect of relative change of 18F-FDG uptake ([baseline – end]/baseline) and baseline 18F-FDG uptake value with type of tumor and type of treatment as level 1 covariates. Results: Nineteen studies (all observational; a total of 438 patients [median, 23 patients per study; range, 10–40]) were included, aiming at the accuracy of PET versus histopathology. To quantify PET, maximum standardized uptake value (SUV) was used in 6 studies, mean SUV in 7, SUV (subtype unclear) in 1, tumor-to-background ratio in 3, and dose uptake ratio in 1. The average overall histopathologic response rate was 0.47 (median, 0.50), ranging from 0.17 to 0.88. The relative change in 18F-FDG uptake was the strongest indicator (P < 0.0001) for tumor response. Baseline 18F-FDG was not significantly associated as a main factor; however, a significant interaction of baseline uptake and relative change after therapy was observed (P < 0.001). Conclusion: Relative change in 18F-FDG uptake was the strongest indicator for tumor response, but the level of baseline 18F-FDG uptake in the primary tumor provided additional information about prediction of response to therapy. These data corroborate and extend the need for standardization, quality assurance, and control of PET studies quantifying 18F-FDG in oncologic treatment monitoring.
- Open Access
- 7 October 2009
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 12 (2) , 225-232
On the Added Value of Baseline FDG-PET in Malignant Lymphoma
- 7 October 2009
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 12 (2) , 225-232
Open AccessOn the Added Value of Baseline FDG-PET in Malignant Lymphoma
- 1 November 2008
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 33 (11) , 780-781
F-18 FDG PET in a Patient With Polycythemia Vera
- 1 November 2008
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 33 (11) , 780-781
F-18 FDG PET in a Patient With Polycythemia Vera